Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 240

1.

Sex Differences in Cardiac Troponin and the Risk of Death or Major Cardiovascular Events.

Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group.

J Am Coll Cardiol. 2016 Aug 30;68(9):978-80. doi: 10.1016/j.jacc.2016.06.013. No abstract available.

PMID:
27561773
2.

Prognostic Value of Adipokines in Predicting Cardiovascular Outcome: Explaining the Obesity Paradox.

Wolk R, Bertolet M, Singh P, Brooks MM, Pratley RE, Frye RL, Mooradian AD, Rutter MK, Calvin AD, Chaitman BR, Somers VK; BARI 2D Study Group.

Mayo Clin Proc. 2016 Jul;91(7):858-66. doi: 10.1016/j.mayocp.2016.03.020. Epub 2016 Jun 9.

PMID:
27289411
3.

Multiple arterial grafts improve survival with coronary artery bypass graft surgery versus conventional coronary artery bypass grafting compared with percutaneous coronary interventions.

Locker C, Schaff HV, Daly RC, Dearani JA, Bell MR, Frye RL, Greason KL, Stulak JM, Joyce LD, Pochettino A, Li Z, Lennon RJ, Lerman A.

J Thorac Cardiovasc Surg. 2016 Aug;152(2):369-379.e4. doi: 10.1016/j.jtcvs.2016.03.089. Epub 2016 Apr 13.

PMID:
27174511
4.

Perioperative Cardiovascular Risk of Prior Coronary Stent Implantation Among Patients Undergoing Noncardiac Surgery.

Mahmoud KD, Sanon S, Habermann EB, Lennon RJ, Thomsen KM, Wood DL, Zijlstra F, Frye RL, Holmes DR Jr.

J Am Coll Cardiol. 2016 Mar 8;67(9):1038-49. doi: 10.1016/j.jacc.2015.11.063.

PMID:
26940923
5.

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes.

Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group.

N Engl J Med. 2015 Aug 13;373(7):610-20. doi: 10.1056/NEJMoa1415921.

6.

On-pump versus off-pump coronary artery bypass graft surgery among patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Singh A, Schaff HV, Mori Brooks M, Hlatky MA, Wisniewski SR, Frye RL, Sako EY; BARI 2D Study Group.

Eur J Cardiothorac Surg. 2016 Feb;49(2):406-16. doi: 10.1093/ejcts/ezv170. Epub 2015 May 11.

PMID:
25968885
7.

A lifelong challenge: conflict resolution.

Frye RL.

J Am Coll Cardiol. 2015 Jan 6;65(1):100. No abstract available.

PMID:
25723045
8.

The prognostic impact of concomitant coronary artery bypass grafting during aortic valve surgery: implications for revascularization in the transcatheter era.

Thalji NM, Suri RM, Daly RC, Greason KL, Dearani JA, Stulak JM, Joyce LD, Burkhart HM, Pochettino A, Li Z, Frye RL, Schaff HV.

J Thorac Cardiovasc Surg. 2015 Feb;149(2):451-60. doi: 10.1016/j.jtcvs.2014.08.073. Epub 2014 Sep 17.

PMID:
25308117
9.

Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial.

Wolk R, Bertolet M, Brooks MM, Pratley RE, Sobel BE, Frye RL, Singh P, Calvin AD, Rutter MK, Mooradian AD, Somers VK; BARI 2D study group.

Eur J Prev Cardiol. 2016 Jan;23(1):50-8. doi: 10.1177/2047487314544046. Epub 2014 Jul 29.

PMID:
25073857
10.

Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".

Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL; BARI 2D Investigators.

Circulation. 2014 Apr 22;129(16):e460-1. doi: 10.1161/CIRCULATIONAHA.113.008033. No abstract available.

11.

Coronary artery bypass in patients with type 2 diabetes: experience from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Sako EY, Brooks MM, Hardison RM, Schaff H, Frye RL.

J Thorac Cardiovasc Surg. 2014 Oct;148(4):1268-72. doi: 10.1016/j.jtcvs.2013.11.038. Epub 2014 Jan 2.

12.

Assessment of coronary artery disease risk in 5463 patients undergoing cardiac surgery: when is preoperative coronary angiography necessary?

Thalji NM, Suri RM, Daly RC, Dearani JA, Burkhart HM, Park SJ, Greason KL, Joyce LD, Stulak JM, Huebner M, Li Z, Frye RL, Schaff HV.

J Thorac Cardiovasc Surg. 2013 Nov;146(5):1055-1063, 1064.e1; discussion 1063-1064. doi: 10.1016/j.jtcvs.2013.06.046. Epub 2013 Sep 4.

13.

Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL; BARI 2D Investigators.

Circulation. 2013 Aug 20;128(8):785-94. doi: 10.1161/CIRCULATIONAHA.112.000678. Epub 2013 Jul 15.

14.

Exercise right heart catheterization for inferior vena cava obstruction: confirming the hemodynamic significance of an anatomic lesion.

Eleid MF, Bjarnason H, Frye RL, Nishimura RA.

Catheter Cardiovasc Interv. 2014 Jan 1;83(1):E105-8. doi: 10.1002/ccd.25062. Epub 2013 Jul 16.

PMID:
23766235
15.

Risk factor control for coronary artery disease secondary prevention in large randomized trials.

Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, Bertolet M, Mathewkutty S, Teo K, Maron DJ, Sethi SS, Domanski M, Frye RL, Fuster V.

J Am Coll Cardiol. 2013 Apr 16;61(15):1607-15. doi: 10.1016/j.jacc.2013.01.044.

16.

Success in recruitment to randomized clinic trials: keep it simple and close to home … or is there more to it?

Frye RL.

J Am Coll Cardiol. 2013 Feb 19;61(7):770-1. doi: 10.1016/j.jacc.2012.11.034. No abstract available.

17.

Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial.

Dagenais GR, Lu J, Faxon DP, Bogaty P, Adler D, Fuentes F, Escobedo J, Krishnaswami A, Slater J, Frye RL; BARI 2D Study Group.

J Am Coll Cardiol. 2013 Feb 19;61(7):702-11. doi: 10.1016/j.jacc.2012.11.036.

18.

Thirty-year trends in outcomes of percutaneous coronary interventions in diabetic patients.

Singh M, Holmes DR Jr, Gersh BJ, Frye RL, Lennon RJ, Rihal CS.

Mayo Clin Proc. 2013 Jan;88(1):22-30. doi: 10.1016/j.mayocp.2012.09.014.

PMID:
23274017
19.

Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Brooks MM, Chaitman BR, Nesto RW, Hardison RM, Feit F, Gersh BJ, Krone RJ, Sako EY, Rogers WJ, Garber AJ, King SB 3rd, Davidson CJ, Ikeno F, Frye RL; BARI 2D Study Group.

Circulation. 2012 Oct 23;126(17):2115-24. doi: 10.1161/CIRCULATIONAHA.112.092973. Epub 2012 Sep 24.

20.

Vorapaxar in the secondary prevention of atherothrombotic events.

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators.

N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk